Compare
Neumora Therapeutics, Inc. vs Editas Medicine, Inc. vs Inhibikase Therapeutics, Inc. vs Instil Bio, Inc.
| Latest fiscal year | Neumora Therapeutics, Inc. NMRA | Editas Medicine, Inc. EDIT | Inhibikase Therapeutics, Inc. IKT | Instil Bio, Inc. TIL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $40.52M | n/a | n/a |
| Revenue growth (YoY) | n/a | +25.4% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -394.9% | n/a | n/a |
| Net margin | n/a | -395.0% | n/a | n/a |
| Net income | -$236.93M | -$160.06M | -$48.26M | -$71.37M |
| EPS (Diluted) | -$1.45 | -$1.80 | -$0.49 | -$10.70 |
| Operating cash flow | -$206.44M | -$165.24M | -$27.79M | -$36.62M |
| Free cash flow | n/a | -$165.85M | -$27.80M | n/a |
| Cash & equivalents | $182.53M | $146.65M | $178.80M | $6.64M |
| Total assets | $191.05M | $186.53M | $181.20M | $203.52M |
| Total liabilities | $87.18M | $159.25M | $8.30M | $89.66M |
| Shareholders' equity | $103.87M | $27.29M | $172.90M | $113.87M |
| Return on year-end equity | -228.1% | -586.6% | -27.9% | -62.7% |
| Shares outstanding | 174.26M | 97.87M | 131.69M | 6.78M |
Revenue, most recent five fiscal years
| Fiscal year | Neumora Therapeutics, Inc. | Editas Medicine, Inc. | Inhibikase Therapeutics, Inc. | Instil Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $40.52M Ended 2025-12-31 | $0 Ended 2024-12-31 | $0 Ended 2021-12-31 |
| 1 year earlier | n/a | $32.31M Ended 2024-12-31 | $260.5K Ended 2023-12-31 | $138.0K Ended 2020-12-31 |
| 2 years earlier | n/a | $78.12M Ended 2023-12-31 | $123.4K Ended 2022-12-31 | n/a |
| 3 years earlier | n/a | $19.71M Ended 2022-12-31 | $3.10M Ended 2021-12-31 | n/a |
| 4 years earlier | n/a | $25.54M Ended 2021-12-31 | $698.5K Ended 2020-12-31 | n/a |